EyePoint Pharmaceuticals (NASDAQ:EYPT) jumps 4.8% in
after-hours trading after announcing that a permanent and specific
J-code for Yutiq (fluocinolone acetonide intravitreal implant) 0.18 mg
three-year micro-insert for chronic, non-infectious uveitis affecting
the posterior segment of the eye is now in effect.
The code, J7314, was issued by the CMS one quarter earlier than under prior CMS policy.
https://seekingalpha.com/news/3503572-eyepoint-insert-uveitis-gets-permanent-j-code
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.